Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) EBITDA Margin (2018 - 2025)

Neurogene's EBITDA Margin history spans 6 years, with the latest figure at 32398.75% for Q1 2025.

  • For Q1 2025, EBITDA Margin fell 59356792.0% year-over-year to 32398.75%; the TTM value through Dec 2025 reached 129158.75%, up 13811808.0%, while the annual FY2024 figure was 8930.27%, N/A changed from the prior year.
  • EBITDA Margin reached 32398.75% in Q1 2025 per NGNE's latest filing, up from 2176.65% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 625966.67% in Q1 2024 to a low of 2176.65% in Q2 2024.
  • Average EBITDA Margin over 3 years is 282088.86%, with a median of 252282.71% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: skyrocketed 15380000bps in 2024, then tumbled -59356792bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 472166.67% in 2023, then tumbled by -100bps to 2176.65% in 2024, then soared by 1588bps to 32398.75% in 2025.
  • Per Business Quant, the three most recent readings for NGNE's EBITDA Margin are 32398.75% (Q1 2025), 2176.65% (Q2 2024), and 625966.67% (Q1 2024).